2024-01-10 07:48:57 ET
DENVER, Colo., Jan. 10, 2023 ( www.247marketnews.com )- Clearmind Medicine Inc. (NASDAQ: CMND) stated, this morning, that the Company completed a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss its clinical trial of its proprietary MEAI-based, CMND-100 compound, for the treatment of Alcohol Use Disorder treatment (AUD) using its novel psychedelic- based therapy.
Clearmind Medicine is trading at $$2.579, up $0.509 (+24.59%), on 1.37M shares traded.
Its 52-week range is $1.919 to $153.00. This often makes short-lived runs, so scalp or quick swing with mental stop loss makes sense.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help …
The post Completed Type A FDA Meeting Making this One to Trade appeared first on 24/7 Market News .
For further details see:
Completed Type A FDA Meeting Making this One to Trade